Espinoza Octavio's most recent trade in Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B was a trade of 224 Common Stock done at an average price of $91.1 . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Other type of transaction at price $ 91.08 per share. | 30 Jun 2025 | 224 | 29,852 (0%) | 0% | 91.1 | 20,401 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 103.89 per share. | 09 May 2025 | 1,000 | 27,432 (0%) | 0% | 103.9 | 103,890 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 104.40 per share. | 09 May 2025 | 500 | 27,932 (0%) | 0% | 104.4 | 52,200 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 32,717 | 32,717 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 7,484 | 26,363 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 115.03 per share. | 04 Mar 2025 | 5,000 | 18,879 (0%) | 0% | 115.0 | 575,149 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 7,390 | 30,709 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 5,429 | 26,076 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 3,803 | 26,906 (0%) | 0% | 120 | 456,360 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 2,757 | 23,319 (0%) | 0% | 120 | 330,840 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 1,221 | 23,879 (0%) | 0% | 120 | 146,520 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 1,024 | 25,882 (0%) | 0% | 120 | 122,880 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 782 | 25,100 (0%) | 0% | 120 | 93,840 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 116.37 per share. | 23 Dec 2024 | 2,104 | 20,647 (0%) | 0% | 116.4 | 244,850 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.51 per share. | 05 Dec 2024 | 1,859 | 22,751 (0%) | 0% | 123.5 | 229,605 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 103.95 per share. | 20 Sep 2024 | 800 | 24,610 (0%) | 0% | 104.0 | 83,160 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 103.86 per share. | 20 Sep 2024 | 275 | 25,410 (0%) | 0% | 103.9 | 28,562 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 103.98 per share. | 20 Sep 2024 | 200 | 25,685 (0%) | 0% | 104.0 | 20,796 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2024 | 1,417 | 466 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 80.72 per share. | 17 Sep 2024 | 1,417 | 25,816 (0%) | 0% | 80.7 | 114,380 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.22 per share. | 17 Sep 2024 | 69 | 25,885 (0%) | 0% | 57.2 | 3,948 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2024 | 69 | 7,240 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.04 per share. | 28 Aug 2024 | 546 | 24,399 (0%) | 0% | 70.0 | 38,242 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2024 | 546 | 0 | - | - | Incentive Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2024 | 207 | 7,309 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.22 per share. | 28 Aug 2024 | 207 | 23,853 (0%) | 0% | 57.2 | 11,845 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Other type of transaction at price $ 60.71 per share. | 28 Jun 2024 | 267 | 23,646 (0%) | 0% | 60.7 | 16,209 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 86.01 per share. | 15 May 2024 | 5,873 | 23,882 (0%) | 0% | 86.0 | 505,148 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 5,022 | 16,179 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 86.67 per share. | 15 May 2024 | 5,022 | 23,513 (0%) | 0% | 86.7 | 435,233 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.84 per share. | 15 May 2024 | 5,022 | 28,535 (0%) | 0% | 52.8 | 265,362 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 86.00 per share. | 15 May 2024 | 2,264 | 21,618 (0%) | 0% | 86.0 | 194,712 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 1,544 | 18,456 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.62 per share. | 15 May 2024 | 1,544 | 23,368 (0%) | 0% | 63.6 | 98,229 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 206 | 7,516 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.22 per share. | 15 May 2024 | 206 | 21,824 (0%) | 0% | 57.2 | 11,787 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 145 | 0 | - | - | Incentive Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 68.74 per share. | 15 May 2024 | 145 | 23,513 (0%) | 0% | 68.7 | 9,967 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 86.65 per share. | 15 May 2024 | 134 | 23,379 (0%) | 0% | 86.6 | 11,611 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 29,272 | 29,272 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Espinoza Octavio | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 7,208 | 28,631 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Espinoza Octavio | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.75 per share. | 27 Feb 2024 | 799 | 29,430 (0%) | 0% | 55.7 | 44,544 | Common Stock |
| Ligand Pharmaceuticals, In... | Espinoza Octavio | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 799 | 2,869 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Espinoza Octavio | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.49 per share. | 27 Feb 2024 | 325 | 29,895 (0%) | 0% | 58.5 | 19,009 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 325 | 1,607 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.22 per share. | 27 Feb 2024 | 140 | 29,570 (0%) | 0% | 57.2 | 8,011 | Common Stock |
| Ligand Pharmaceuticals, In... | Espinoza Octavio | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 140 | 7,722 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Espinoza Octavio | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 88.46 per share. | 27 Feb 2024 | 140 | 29,755 (0%) | 0% | 88.5 | 12,384 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.65 per share. | 15 Feb 2024 | 1,479 | 21,423 (0%) | 0% | 74.6 | 110,407 | Common Stock |
| Ligand Pharmaceuticals, In... | Espinoza Octavio | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.61 per share. | 05 Dec 2023 | 1,269 | 22,902 (0%) | 0% | 59.6 | 75,645 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Other type of transaction at price $ 56.78 per share. | 30 Jun 2023 | 375 | 24,517 (0%) | 0% | 56.8 | 21,293 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 16,419 | 16,419 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 6,046 | 24,142 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.98 per share. | 15 Feb 2023 | 849 | 18,096 (0%) | 0% | 73.0 | 61,960 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Other type of transaction at price $ 56.78 per share. | 30 Dec 2022 | 275 | 18,945 (0%) | 0% | 56.8 | 15,615 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 6,620 | 6,620 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2022 | 20,000 | 20,000 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2022 | 11,000 | 18,670 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.90 per share. | 30 Nov 2022 | 1,187 | 7,670 (0%) | 0% | 72.9 | 86,532 | Common Stock |
| Ligand Pharmaceuticals, In... | Octavio Espinoza | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 75.64 per share. | 09 Nov 2022 | 1,696 | 8,857 (0%) | 0% | 75.6 | 128,283 | Common Stock |